Latest News and Press Releases
Want to stay updated on the latest news?
- 
                            
BOSTON and SAN FRANCISCO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Snyk, the AI Security Company, and Cognition, the company behind the leading autonomous AI software engineer Devin and the agentic IDE...
 - 
                            
GNE 2025, Nov 10-14 in Dallas, will showcase how NaaS for AI, secure networking, automation, and next-gen infrastructure are redefining digital services.
 - 
                            
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- For the first time, a study shows a digital assessment can provide a scientific measure of acetylcholine – a key brain chemical whose decline signals...
 - 
                            
The first patient has been dosed in Tisento's global Phase 2b PRIZM study investigating zagociguat in MELAS.
 - 
                            
Toronto, Canada, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Creyos, a leader in cognitive and behavioral health assessment, has announced significant enhancements to its online platform to improve...
 - 
                            
A clinical study, published in the journal Food Science and Nutrition, showed that GBL-Memory1, a unique combination of L-theanine and Fructooligosaccharides, can improve memory by up to 10.1%...
 - 
                            
Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a...
 - 
                            
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting...
 - 
                            
LAS VEGAS, July 08, 2021 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based products for heart and brain...
 - 
                            
Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS;...